Wockhardt was in action on Monday after the drug maker said the US health regulator agreed to abridged clinical trials for antibiotic being developed by the company. Wockhardt recorded a jump of 6.46 percent in share price on Monday.
The company is developing superdrug antibiotic WCK 5222. The drug is expected to be a life-saving therapy for serious hospital acquired infections. The aforesaid US FDA approval will help Wockhardt to speed up phase III clinical trials for the drug.
Heckyl Technologies, a leading news sentiment and market data analytics firm, has conducted a study to highlight how a trader can use sentiment scores to predict impending stock price movement. We have analyzed news sentiment data for 246 Canadian companies listed on Toronto Stock Exchange (TSX) from January 2016 to July 2016. On numerous occasions, our sentiment score has acted as a leading indicator for the share price movement of 213 companies or 87% of the total sample size.
Read the rest of this entry »